Epidemiological evidence suggests a close link between hyperuricemia and the high prevalence of hypertension and chronic kidney disease (CKD), suggesting that uric acid (UA) can be a precipitating factor for the progression of renal diseases. Clinical studies to investigate whether the UA-lowering therapy is renal protective appears to be of importance to prove this causal relationship. A recent meta- analysis revealed that UA-lowering therapies with the two forerunner xanthine oxidoreductase (XOR) inhibitors, allopurinol and febuxostat, may be beneficial for the progression of hypertension and CKD. In comparison, basic and clinical information of the renal benefit with a novel non-purine selective XOR inhibitor, topiroxostat (TPX), has not been fully investigated.
This review specifically highlights the currently available evidence on TPX that has been proven as efficacious as the other two formerly available XOR inhibitors in lowering serum UA levels as well as reducing urinary albumin excretion in patients with hyperuricemia or gout.